Theriva Biologics financials
$0.2100−3.00%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $300.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $300.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | 100.0% | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$3.3M | -$2.1M | -$2.1M | -$4.4M | -$13.1M | -$4.4M | -$4.6M | -$7.9M | -$8.5M | -$5.4M | -$6.2M | -$4.2M |
| Net income | -$3.2M | -$2.0M | -$3.5M | -$4.4M | -$13.1M | -$4.3M | -$4.4M | -$7.7M | -$8.3M | -$5.2M | -$5.5M | -$3.3M |
| Net margin | — | −681.3% | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.07 | $-0.05 | $-0.12 | $-0.45 | $-1.93 | $-1.55 | $-1.59 | $-6.81 | $-10.72 | $-7.53 | $-4.10 | $-4.85 |
| EBITDA | -$3.3M | -$2.1M | -$2.0M | -$4.4M | -$13.1M | -$4.4M | -$4.6M | -$5.0M | -$4.4M | -$5.4M | -$6.2M | -$4.2M |
| Operating cash flow | -$3.1M | -$2.5M | -$2.9M | -$4.3M | -$4.7M | -$4.8M | -$4.7M | -$3.9M | -$3.5M | -$4.9M | -$6.9M | -$1.4M |
| Free cash flow | -$3.1M | -$2.5M | -$2.9M | -$4.3M | -$4.7M | -$4.8M | -$4.7M | -$3.9M | -$3.5M | -$4.9M | -$6.9M | -$1.5M |
| Diluted shares | 45.9M | 41.1M | 29.4M | 9.7M | 6.8M | 2.8M | 2.8M | 1.1M | 0.8M | 0.7M | 1.3M | 0.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $11.3M | $14.4M | $13.1M | $7.5M | $12.1M | $10.0M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $1.7M | $1.7M | $1.7M | $1.7M | $1.7M | $1.6M |
| Total assets | $34.9M | $38.2M | $38.2M | $30.8M | $35.8M | $32.2M |
| Total liabilities | $22.7M | $22.8M | $22.9M | $24.1M | $25.2M | $16.7M |
| Shareholders' equity | $12.2M | $15.4M | $15.4M | $6.7M | $10.6M | $15.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology